Board of Directors

COMMITTED TO CHANGING THE FACE OF CANCER TREATMENT

 

The BioCanRx Board of Directors is responsible for ensuring financial accountability, scientific excellence, knowledge exchange and operational efficiency. The board approves policies and procedures consistent with the goals and mission of the network. It also determines the mandate, membership, authority and makeup of committees.

 

The Board provides leadership and direction to BioCanRx so that it remains on target with respect to its strategic plan and commitment to the NCE mandate.

 

MEMBERS OF THE BOARD:

newport_small

eborenstein
Ken Newport
Chair, Board of Directors
Dr. John Bell
Scientific Director, BioCanRx
Senior Scientist, The Ottawa Hospital
Professor, uOttawa
Ela Borenstein
Program Director
Business Development Bank of Canada (BDC)
Dr. Josée Brisebois
Head of Medical, Incyte Canada / Medical Affairs with oversight of Clinical & Regulatory Affairs
cearle
kessabar
dlynkowski
Craig Earle
Vice-President, Cancer Control at the Canadian Partnership Against Cancer
Karimah Es Sabar
Chief Executive Officer & Partner, Quark Venture Inc.
Doreen Hume
Partner, Audit & Assurance, Deloitte Canada
Debra Lynkowski
Chief Operating Officer
The Ottawa Hospital Research Institute
Antonia Palmer
Co-Founder at Ac2orn: Advocacy for Canadian Childhood Oncology Research Network
Dr. David Poon
Vice President Business Development and Alliance Management, Zymeworks Inc.
Dr. John Stagg
Associate Professor, Faculty of Pharmacy at the University of Montreal
Lab Head at the CHUM Hospital Research Centre
Dr. Christine Williams
Deputy Director, Ontario Institute for Cancer Research (OICR)
Russell Williams
Senior Vice President, Mission, Diabetes Canada

 

EX-OFFICIO MEMBERS (NON-VOTING)

 

smichaud
Dr. Stéphanie Michaud
President and CEO, BioCanRx
Secretary, Board of Directors

 

OBSERVERS

 

     
François Santerre
Senior Program Manager, College and Networks, Networks of Centres of Excellence (NCE)